New Year brings new look at khondrion.com

Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, starts 2019 with the launch of its new website.As the company continues to advance its proprietary science through a wholly-owned clinical and...

Scientific publication in Cell Death & Disease

Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the Netherlands – November 2018: Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies...

Jan Smeitink interview with Catalyze

In July 2018 Khondrion was awarded €2.3M funding from the EU Horizon 2020 Research and Innovation programme to progress clinical development of KH176, its lead pipeline asset. Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, talks to Catalyze®, who...

Publication of the KHENERGY study results

KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.NIJMEGEN, the Netherlands:...